J Viral Hepat:丙型肝炎病毒相关并发症在女性退伍军人中逐渐增加

2017-08-30 MedSci MedSci原创

女性HCV并发症的发生率和患病率呈上升趋势。女性肝硬化并发症的上升速度与男性相似。HCV治疗的好处需要扩展到所有患者,以遏制HCV并发症的上升趋势。

丙型肝炎病毒(HCV)感染的流行病学和临床过程中存在性别差异。然而,很少有长期的纵向研究对女性严重肝并发症的发病率和患病率进行研究。

为完善对这一问题的认识,2000年1月-2013年12月,研究者利用全美退伍军人队列数据库,来确认丙型肝炎病毒阳性的退伍军人。对年龄、糖尿病、艾滋病和嗜酒进行调整后,研究者计算了性别特异性的年发病率、肝硬化、失代偿性肝硬化和肝细胞癌(HCC)患病率。在Joinpoint软件,采用分段线性回归来计算每个性别结果的平均年百分比变化(AAPC)。

研究结果表明,在2000-2013年间,264409例退伍老军为HCV感染者,其中7162例(2.7%)的HCV感染者为女性。随着时间的推移,男性和女性肝硬化、失代偿性肝硬化和肝癌的发病率有明显的上升。在研究期间,男性年调整肝硬化、失代偿性肝硬化和肝癌的发病率高于女性。然而,男性和女性并发症增长速度相似。肝硬化、失代偿性肝硬化、肝细胞癌在男性的平均年百分比变化(AAPC)分别是13.1、15.6、21.0;女性的肝硬化、失代偿性肝硬化、肝细胞癌的平均年百分比变化(AAPC)分别是15.2、16.9、25.3。在流行分析中,结果是相似的,虽然对每个结果,AAPCs略小。

综上所述,女性HCV并发症的发生率和患病率呈上升趋势。女性肝硬化并发症的上升速度与男性相似。HCV治疗的好处需要扩展到所有患者,以遏制HCV并发症的上升趋势。

原始出处:

Kramer JR, El-Serag HB, Taylor TJ, et al. Hepatitis C virus-related complications are increasing in women veterans: A national cohort study. J Viral Hepat, 2017, Aug 16. doi: 10.1111/jvh.12728.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1757845, encodeId=f2281e57845ae, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Mar 19 00:06:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648677, encodeId=231216486e719, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Tue Sep 19 17:06:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800310, encodeId=2c01180031087, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Nov 05 20:06:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239582, encodeId=3f512395823f, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sat Sep 02 07:08:17 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239346, encodeId=77ce2393463c, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Fri Sep 01 14:59:27 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274596, encodeId=b30412e459686, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426812, encodeId=be3f142681208, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429540, encodeId=86ab14295402a, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
    2018-03-19 丁鹏鹏
  2. [GetPortalCommentsPageByObjectIdResponse(id=1757845, encodeId=f2281e57845ae, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Mar 19 00:06:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648677, encodeId=231216486e719, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Tue Sep 19 17:06:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800310, encodeId=2c01180031087, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Nov 05 20:06:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239582, encodeId=3f512395823f, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sat Sep 02 07:08:17 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239346, encodeId=77ce2393463c, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Fri Sep 01 14:59:27 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274596, encodeId=b30412e459686, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426812, encodeId=be3f142681208, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429540, encodeId=86ab14295402a, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1757845, encodeId=f2281e57845ae, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Mar 19 00:06:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648677, encodeId=231216486e719, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Tue Sep 19 17:06:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800310, encodeId=2c01180031087, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Nov 05 20:06:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239582, encodeId=3f512395823f, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sat Sep 02 07:08:17 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239346, encodeId=77ce2393463c, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Fri Sep 01 14:59:27 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274596, encodeId=b30412e459686, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426812, encodeId=be3f142681208, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429540, encodeId=86ab14295402a, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1757845, encodeId=f2281e57845ae, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Mar 19 00:06:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648677, encodeId=231216486e719, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Tue Sep 19 17:06:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800310, encodeId=2c01180031087, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Nov 05 20:06:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239582, encodeId=3f512395823f, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sat Sep 02 07:08:17 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239346, encodeId=77ce2393463c, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Fri Sep 01 14:59:27 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274596, encodeId=b30412e459686, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426812, encodeId=be3f142681208, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429540, encodeId=86ab14295402a, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
    2017-09-02 1dd8c52fm63(暂无匿称)

    学习学习.了解了解

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1757845, encodeId=f2281e57845ae, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Mar 19 00:06:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648677, encodeId=231216486e719, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Tue Sep 19 17:06:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800310, encodeId=2c01180031087, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Nov 05 20:06:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239582, encodeId=3f512395823f, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sat Sep 02 07:08:17 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239346, encodeId=77ce2393463c, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Fri Sep 01 14:59:27 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274596, encodeId=b30412e459686, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426812, encodeId=be3f142681208, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429540, encodeId=86ab14295402a, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
    2017-09-01 往日如昨

    学习了谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1757845, encodeId=f2281e57845ae, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Mar 19 00:06:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648677, encodeId=231216486e719, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Tue Sep 19 17:06:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800310, encodeId=2c01180031087, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Nov 05 20:06:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239582, encodeId=3f512395823f, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sat Sep 02 07:08:17 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239346, encodeId=77ce2393463c, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Fri Sep 01 14:59:27 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274596, encodeId=b30412e459686, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426812, encodeId=be3f142681208, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429540, encodeId=86ab14295402a, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1757845, encodeId=f2281e57845ae, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Mar 19 00:06:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648677, encodeId=231216486e719, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Tue Sep 19 17:06:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800310, encodeId=2c01180031087, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Nov 05 20:06:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239582, encodeId=3f512395823f, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sat Sep 02 07:08:17 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239346, encodeId=77ce2393463c, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Fri Sep 01 14:59:27 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274596, encodeId=b30412e459686, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426812, encodeId=be3f142681208, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429540, encodeId=86ab14295402a, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
    2017-09-01 仁心济世
  8. [GetPortalCommentsPageByObjectIdResponse(id=1757845, encodeId=f2281e57845ae, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Mar 19 00:06:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648677, encodeId=231216486e719, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Tue Sep 19 17:06:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800310, encodeId=2c01180031087, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Nov 05 20:06:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239582, encodeId=3f512395823f, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sat Sep 02 07:08:17 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239346, encodeId=77ce2393463c, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Fri Sep 01 14:59:27 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274596, encodeId=b30412e459686, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426812, encodeId=be3f142681208, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429540, encodeId=86ab14295402a, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Sep 01 13:06:00 CST 2017, time=2017-09-01, status=1, ipAttribution=)]

相关资讯

J Gastroen Hepatol:丙型肝炎直接抗病毒疗法效果比较

3种直接抗病毒药物均表现出较高的持续病毒学应答率

Liver Int :ombitasvir, Paritaprevir/+Dasabuvir+Ribavirin对基因1b型丙型肝炎肝硬化患者的疗效和安全性分析

OBV/PTV/r+DSV+RBV的治疗方案被证明疗效显著,96.6%的患者可获得SVR。严重不良事件的比率为61/2070(2.9%),不良反应大多数是失代偿性肝硬化,与肝功能障碍、血小板数量减少有关。

Am J Obstet Gynecol:关于妊娠女性感染HCV的筛查、治疗和管理指南。

母胎医学关于筛查、治疗和管理孕期HCV感染的指南。

J Hepatol:乙型肝炎、丙型肝炎晚期与疾病失代偿和肝细胞癌发生相关

随着时间推移,肝炎晚期的比率已经下降。乙型肝炎和丙型肝炎晚期的患者错失了降低严重肝病风险的机会;使用基于风险的测试和重视那些被忽视的群体,比如那些没有定期看医生及那些患有严重精神疾病的患者,可以提高早期诊断成功率。

SCI REP:乙型肝炎和丙型肝炎病毒感染与糖尿病有何关系?

在这个糖尿病风险较低的大型人群中,HBV和HCV感染与糖尿病患病率相关,并且HBV感染与糖尿病的发生风险相关。该研究增加了证据表明糖尿病是HBV和HCV感染的一个额外代谢并发症。

J Gastroen Hepatol:糖尿病加速HCV感染者的癌变进程

对于HCV感染患者,糖尿病会增加患者肝细胞癌的发病率以及全因死亡率